In breast cancer, BET members differentially regulate an aggressive phenotype with BRD2 as a positive regulator of epithelial-to-mesenchymal transition (EMT) and BRD3 and BRD4 as repressors of this program [180]. The gene discussed is BRD4; the disease is breast cancer.